Current Oncology · 2023 · 24 citations · 38 references
MedicineOncologyPharmacologyChemotherapyTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyCytokines In Tumor ImmunityOvarian CancerTargeted Cancer TherapyTargeted TherapyTumor Microenvironment ModulationOvarian Cancer ChemotherapyOvarian Cancer TreatmentOvarian Cancer Tumor MicroenvironmentParp InhibitionPoly Adp-ribose Polymerase InhibitorsPoly(adp-ribose) Polymerase InhibitionPoly(adp-ribose) Polymerase InhibitorsRecurrent Ovarian Cancer
Despite high response rates to initial therapy, most patients with ovarian cancer will ultimately recur and go on to develop resistance to standard treatments. Novel therapies have been developed to overcome drug resistance and alter the tumor immune microenvironment by targeting oncogenic pathways, activating the innate immune response, and enhancing drug delivery. In this review, we discuss the current and future roles of chemotherapy, targeted agents such as poly (ADP-ribose) polymerase (PARP) inhibitors, bevacizumab, and mirvetuximab in the treatment of ovarian cancer. We explore the emerging role of therapeutic targets, including DNA repair pathway inhibitors and novel antibody-drug conjugates. Furthermore, we delve into the role of immunotherapeutic agents such as interleukins as well as immune-promoting agents such as oncolytic viruses and cancer vaccines. Innovative combination therapies using these agents have led to a rapidly evolving treatment landscape and promising results for patients with recurrent ovarian cancer.
38
Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle et al. · CA A Cancer Journal for Clinicians · 2023 · 16.7K citations · Full text
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Narciso Olvera et al. · Nature · 2011 · 8.2K citations · Full text
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text
Medicine, Oncology, Pharmacology +15
Carol Aghajanian, Stephanie V. Blank, Barbara A. Goff et al. · Journal of Clinical Oncology · 2012 · 1.4K citations · Full text
Medicine, Gynecology, Oncology +16